Fig. 1From: Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completionProportion of patients receiving denosumab or zoledronic acid who developed hypocalcaemia of any grade. Figure reproduced with permission from Body et al. Eur J Cancer 2015;51:1812–21 under the Creative Commons licence (https://creativecommons.org/licenses/by-nc-nd/4.0/) [11]Back to article page